lind-peinture
» » Hypercalcemia of Malignancy (Recent Results in Cancer Research)

eBook Hypercalcemia of Malignancy (Recent Results in Cancer Research) ePub

by Friedhelm Raue

eBook Hypercalcemia of Malignancy (Recent Results in Cancer Research) ePub
Author: Friedhelm Raue
Language: English
ISBN: 3540576312
ISBN13: 978-3540576310
Publisher: Springer; 1 edition (December 6, 1994)
Pages: 163
Category: Medicine & Health Sciences
Subcategory: Other
Rating: 4.9
Votes: 911
Formats: txt lrf mbr mobi
ePub file: 1247 kb
Fb2 file: 1810 kb

Hypercalcemia of Malignancy. Bibliographic Information. Hypercalcemia of Malignancy.

Hypercalcemia of Malignancy.

Similarly, a recent US study reported a hypercalcaemia prevalence of. .

Similarly, a recent US study reported a hypercalcaemia prevalence of 2–. % among all patients with cancer, ranging from . –2. 1% in prostate cancer, to . –10. 2% in multiple myeloma. Hypercalcaemia and hypocalcaemia: finding the balance. Calcium metabolism in cancer and hypercalcaemia of malignancy: The balance between bone formation and resorption may be disrupted in patients with cancer, leading either to increased bone resorption, calcium release, and possibly hypercalcaemia, or to increased bone formation, sequestration of calcium, and possibly hypocalcaemia.

The estimated annual incidence rate of hypercalcemia of malignancy is about 150 new cases per million population per year (Mundy et al. 1980). It is likely to affect 20%–40% of patients with malignancies during the course of their disease.

Background: d hypercalcemia (MAHC) is the .

Background: d hypercalcemia (MAHC) is the most common cause of hypercalcemia among hospitalized patients. MAHC can result from the production of parathyroid hormone related peptide (PTHrP) which is known as humoral hypercalcemia of malignancy (HHM). Background: The reported proportion of cancer patients who experience hypercalcemia of malignancy (HCM) ranges between 3% and 30%. HCM can be observed with any type of tumor and occurs most commonly in lung cancer, breast cancer and multiple myeloma.

Hypercalcemia is generally the symptom of a disease which requires treatment

Hypercalcemia is generally the symptom of a disease which requires treatment. Only in rare conditions such as hypocalciuric hypercalcemia or truly asymptomatic, nonprogressive primary hyperparathyroidism is observation of hypercalcemia without treatment justified. In such cases, hypercalcemia is mild. Severely elevated plasma levels regardless of the underlying disease cause symptoms which are summarized as the hypercalcemic syndrome (Table 1). All such symptoms are functional and can be reversed.

Hypercalcemia of Malignancy book. The pathophysiological, epidemiological and clinical aspects of hypercalcemia of malignancy are presented in this issue, with a focus on the recently discovered humoral factor responsible for the development of hypercalcemia.

cle{, title {Hypercalcemia of Malignancy}, author {M. journal {Archives of internal medicine}, year {1987}, volume {147 7}, pages {.

The reported proportion of cancer patients who experience hypercalcemia of malignancy (HCM) ranges between 3% and 30%. While HCM is a potentially fatal condition, the prevalence of HCM is not well defined. Hypercalcemic patients (CSC ≥ 1. mg/dL) were classified into 4 CSC levels.

The clinical features of hypercalcemia of malignancy resemble primary hyperparathyroidism. Are There Any Factors That Might Affect the Lab Results?

The clinical features of hypercalcemia of malignancy resemble primary hyperparathyroidism. Patients may present either with vague, nonspecific symptoms (fatigue, muscle weakness, mental disturbances) or with symptoms more obviously related to hypercalcemia, such as kidney stones. The initial biochemical work-up of hypercalcemia consists of serum calcium, PTH, albumin, thyroid function tests (. TSH, free thyroxine), and measures of kidney function (. blood urea nitrogen, creatinine). A combination of hypercalcemia with low PTH should prompt a follow-up test of PTHrP. Are There Any Factors That Might Affect the Lab Results?

Электронная книга "Hypercalcemia of Malignancy", Friedhelm Raue.

Электронная книга "Hypercalcemia of Malignancy", Friedhelm Raue. Эту книгу можно прочитать в Google Play Книгах на компьютере, а также на устройствах Android и iOS. Выделяйте текст, добавляйте закладки и делайте заметки, скачав книгу "Hypercalcemia of Malignancy" для чтения в офлайн-режиме.

Hypercalcemia is the most common life-threatening metabolic disorder associated with cancer. The pathophysiological, epidemiological and clinical aspects of hypercalcemia of malignancy are presented in this issue, with a focus on the recently discovered humoral factor responsible for the development of hypercalcemia. With a better understanding of the pathophysiology of this condition and the development of new potent drugs, capable of inhibiting bone resorption, especially bisphosphonates, the clinician will be more successful in correcting hypercalcemia in the great majority of patients.
lind-peinture.fr
© All right reserved. 2017-2020
Contacts | Privacy Policy | DMCA
eBooks are provided for reference only